Key Transaction Details

  • Entity Involved: Australian subsidiary Noumed Pharmaceuticals Pty Ltd
  • Counterparty: Australia's leading pharmacy networks (multi-billion-dollar pharmacy chains)
  • Agreement Type: Exclusive OTC Medicines Supply Agreement renewal
  • Agreement Value: AUD 202 million (approximately INR 1300 crores at exchange rate 1 AUD = INR 64.5)
  • Annual Value: Approximately AUD 27 million per annum
  • Agreement Term: 7½ years (extendable by additional 3 years upon mutual consent)
  • Effective Date: 1st July 2026
  • Product Expansion: Targets addition of 12 new products every year

Strategic and Operational Details

Noumed Pharmaceuticals will continue as exclusive supplier of comprehensive OTC pharmaceutical products across Australia, managing the full value chain including:

  • Manufacturing and product sourcing
  • Regulatory compliance and TGA registrations
  • Warehousing and quality assurance
  • Nationwide distribution

The agreement is structured for continuous growth with steadily increasing contract value and scope every year over its life.

Management Commentary

Mr. Anil Kumar Karusala, Managing Director: Stated that the renewal reflects confidence from Australia's leading pharmacy groups and provides a platform for future expansion into other highly regulated markets. Expected to generate sustainable, predictable revenues and create long-term value.

Mr. Mark Thulborne, CEO, Noumed Pharmaceuticals: Emphasized that the long tenure signifies capability to build lasting customer relationships and deliver quality products on time in one of the world's most regulated pharmaceutical markets.

Financial Impact

The agreement provides predictable, recurring revenues across the 7½-year horizon (potentially extendable to over a decade). Financial impact quantified as AUD 202 million total contract value.

Strategic Benefits Disclosed

  • Locks in predictable, recurring revenues
  • Cements Noumed's presence in Australian OTC market
  • Expands Sai Parenterals' international pharmaceutical business
  • Enhances manufacturing scale and operating leverage
  • Supports continuous launch of new OTC products
  • Deepens relationship with Australia's largest pharmacy retail groups
  • Improves utilization of regulatory and manufacturing infrastructure
  • Increases global presence in regulated pharmaceutical markets
  • Enhances credibility as preferred international pharmaceutical partner
  • Provides stronger, longer-duration earnings visibility

Forward-looking Statements

The document includes disclaimer noting that certain statements are forward-looking and subject to risks including significant changes in economic environment, tax laws, inflation, litigation, etc. Company undertakes no obligation to publicly update these statements.